WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

13.07.2017: Press release: WILEX reports first half 2017 results: WILEX AG today published its financial report for the first six months of 2017 (1 December 2016 - 31 May 2017). ...More

 

 

 

 

Seite gelesen: 110150 | Heute: 266